How do we improve predictions of drug concentration-time profiles?

5th FDA/PQRI Conference 'on Advancing Product Quality: Advancing Quality & Technology of Future Pharmaceuticals'

SwatiNagar, Ph.D.

ΠП

December 1, 2021


Department of Pharmaceutical Sciences

Temple University School of Pharmacy

Outline


- Drug absorption and distribution the membrane as a barrier
 - Membrane permeability, membrane partitioning, and membrane transporters
- Models to predict absorption
 - A continuous (PDE-based) absorption model
 - Modeling permeability-, dissolution-, and solubility-limited absorption
- The utility of pre-clinical absorption models as proof-of-concept
 - Modeling food effects, particle size, and uptake/efflux transporters
- Future directions

Membrane partitioning and permeability





Nagar & Korzekwa 2012, DMD 40:1649-1652; Korzekwa et al. 2012, DMD 40: 865-876; Nagar et al 2013, Pharm Res 31: 347-359.

Membrane partitioning, permeability, and transporters: e.g., P-gp



4






Jin 2012; Nature, 490:566-9.

- P-gp concerns in drug therapy:
- At the BBB (substrates)
- In the intestine (substrates and inhibitors)


Nagar & Korzekwa 2012, DMD 40:1649-1652; Korzekwa et al. 2012, DMD 40: 865-876; Nagar et al 2013, Pharm Res 31: 347-359.

Compartmental models for oral absorption




5

Suzuki, Higuchi, and Ho, 1970, J Pharm Sci 59:651-659.




Yu and Amidon, 1999, Int J Pharm 186:119-125.



Agoram et al, 2001, Adv Drug Deliv Rev 50:S41-S67.


Prediction of drug absorption

6




Ni et al 1980, Int J Pharm 5: 33-47; Nagar, Korzekwa RC, and Korzekwa K 2017, Mol Pharmaceutics 14:3069-3086.


Modeling intestinal physiology






Atenolol solution dose








Drug Dissolution and Precipitation


 For dissolution of drug particles, the equation proposed by Wang and Flanagan was modified as follows:

$$f_{\rm diss}(x, t) = \left(8C_{\rm part}(x, t)\pi D_{3}\sqrt{\frac{3C_{\rm solid}(x, t)}{4\pi\rho C_{\rm part}(x, t)}}\right)(S - C_{\rm l}(x, t))$$

- Basing drug amount on the particle size and number allows us to retain the number of particles in the system.
- These particles with minimal mass continue to move along the intestine.
- These particles can then be used for precipitation.


Nifedipine Precipitation






Modeling OATP and P-gp Content


a Intestinal epithelia




Giacomini et al, Nature Reviews Drug Discovery 2010, 9:215-236.




Protein abundance from Drozdzik, M., et al. Mol Pharmaceutics **11**, 3547-3555 (2014).






Rat absorption model to incorporate food effects, particle size effects, and intestinal CYP inhibition




Predicting Concentration-time profiles...are we there yet? (Absorption, distribution, elimination)


Perfusion-limited distribution in traditional PBPK



17



Permeability-limited distribution in a new PBPK framework



Ye, Biopharm Drug Dispos 2016;37:123-141

Korzekwa et al, manuscripts under review

Summary and Future Directions

- Modeling membranes as explicit compartments can greatly improve absorption and distribution predictions
- We have developed a continuous absorption model that is completely flexible. Drug permeability, partitioning, and active transport can be incorporated into this model
- Complexities such as food and formulation effects, transporters, enzyme activity, and inhibition can be modeled to evaluate their impact of drug absorption and bioavailability
- Future Directions
 - Develop rat and mouse absorption models to incorporate experimental and physiological complexities into mathematical models for absorption
 - Characterize the impact of pH on permeability
 - Develop a more efficient method to incorporate enterohepatic recycling

Acknowledgments

- Nagar Lab
 - Casey Radice, PhD
 - Tirtha Nandi
- Korzekwa Lab
 - Kim Holt, PhD
 - Min Ye
- Richard Korzekwa, PhD

- Funding
 - NIH/NIGMS R01GM114369
 - NIH/NIGMS R01GM104178

